Results 221 to 230 of about 54,702 (261)
Some of the next articles are maybe not open access.
Esomeprazole: a proton pump inhibitor
Expert Review of Gastroenterology & Hepatology, 2009Proton pump inhibitors (PPIs) are the most potent inhibitors of gastric acid secretion available, and they are effective for treating all acid-related disorders. Esomeprazole is one of several most recent PPIs that became available to the market in 2001.
Ravi, Vachhani +2 more
openaire +2 more sources
Current Opinion in Gastroenterology, 2012
This review summarizes adverse effects of potential proton pump inhibitors (PPIs), including nutritional deficiencies (B12 and magnesium), rebound acid hypersecretion, acute interstitial nephritis, gastric carcinoid tumor, cardiovascular risk with clopidogrel and PPI coprescription, bone fractures, enteric infections and pneumonia.
Saman, Chubineh, John, Birk
openaire +4 more sources
This review summarizes adverse effects of potential proton pump inhibitors (PPIs), including nutritional deficiencies (B12 and magnesium), rebound acid hypersecretion, acute interstitial nephritis, gastric carcinoid tumor, cardiovascular risk with clopidogrel and PPI coprescription, bone fractures, enteric infections and pneumonia.
Saman, Chubineh, John, Birk
openaire +4 more sources
Lansoprazole: A Proton Pump Inhibitor
Annals of Pharmacotherapy, 1996OBJECTIVE: To summarize the published data on lansoprazole, a proton pump inhibitor approved by the Food and Drug Administration for use in the treatment of duodenal ulcer, erosive esophagitis, and pathologic hypersecretory conditions (e.g., Zollinger-Ellison syndrome).
openaire +2 more sources
Pharmacogenomics of proton pump inhibitors
Pharmacogenomics, 2004Proton pump inhibitors (PPIs), such as omeprazole, lansoprazole, rabeprazole, esomeprazole, and pantoprazole, are metabolized by cytochrome P450 isoenzyme 2C19 (CYP2C19) in the liver. There are genetic differences that affect the activity of this enzyme. The genotypes of CYP2C19 are classified into three groups: homozygous extensive metabolizer (homEM),
Takahisa, Furuta +4 more
openaire +2 more sources
Proton Pump Inhibitors and Mortality
Gastroenterology, 2023Helge L. Waldum, Reidar Fossmark
openaire +2 more sources
Association of Proton Pump Inhibitor Use With All-Cause and Cause-Specific Mortality
Gastroenterology, 2022, Chun-Han Lo, Raaj S Mehta
exaly
PROTON PUMP INHIBITORS IN INFANTS
Journal of Pediatric Gastroenterology and Nutrition, 2005Thomas P. Iarocci +6 more
openaire +1 more source